Samsung Bioepis gets approval to sell biosimilar in Europe

EPYSQLI, a biosimilar of the rare blood disease treatment Soliris, is the company’s seventh biosimilar approved for use in Europe

Samsung Bioepis gets approval to sell biosimilar in Europe
Dae-Kyu Ahn 1
2023-05-31 10:47:41 powerzanic@hankyung.com
Bio & Pharma

South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patients with paroxysmal nocturnal hemoglobinuria (PNH).

The company on Tuesday said it obtained approval from the European Commission for EPYSQLI™(Eculizumab). 

Developed by the Boston-based Alexion Pharmaceuticals, Soliris is a treatment for intractable rare diseases such as paroxysmal nocturnal hemoglobinuria but its annual cost is well out of reach for most people at 400 million ($303,431) to 500 million won.

Samsung Bioepis now has seven biosimilars on the European market including EPYSQLI.

Industry observers say Samsung Bioepis has secured the first pipeline in the blood sector by breaking through the biosimilar niche market, which is marked by high development difficulty.

"EPYSQLI demonstrated equivalence through comparative clinical trials with the original drug to improve patient accessibility to ultra-expensive medicine," said Jang Jun-ho, a professor at the Department of Hematology and Oncology of Samsung Medical Center in Seoul who was in charge of the biosimilar's Phase 3 clinical trials.

"Treatment opportunities for many patients and contribution to fiscal savings are now possible," a bio industry source said.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com
#Samsung Bioepis #biosimilar #Soliris #rare blood diseases #Europe #approval #European market #EPYSQLI

Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada

Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada

Researchers of Samsung Bioepis(Courtesy of Samsung Bioepis) Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the treatment of eye diseases, including age-related macular degeneration (ARMD), in Germany a

Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

Samsung Bioepis headquarters  NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in the eye disease-related biosimilar segment, particularly for the treatment of macular degeneration, the global ma

Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Solaris

Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Solaris

A researcher at Samsung Bioepis conducts a drug test Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare blood disease medicine, Solaris, has shown the same clinical effects.While presenting the result

Samsung Bioepis to double biosimilars, may resume Nasdaq listing plans

Samsung Bioepis to double biosimilars, may resume Nasdaq listing plans

A researcher at Samsung Bioepis conducts a drug test Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, plans to double the number of its biosimilar products on sale to 10 by 2025 and accelerate its push for the development of novel therapeutics.With its increasing biosimilar reven

Samsung Bioepis posts $1.26 billion in global biosimilar sales

Samsung Bioepis posts $1.26 billion in global biosimilar sales

A Samsung Bioepis researcher Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said on Friday that sales of its five biosimilar products in global markets, excluding South Korea, reached $1.26 billion in 2021, up 11% from the previous year.In 2020, global sales of the company&rsqu

Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz

Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz

Korean biopharmaceutical firms are racing for the development of biosimilars Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byooviz, a biosimilar referencing Lucentis for the treatment of macular dege

Samsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe

Samsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe

A researcher at Samsung Bioepis conducting a drug test South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology biosimilar of Lucentis, expanding its product portfolio, which has been focusing on existing aut
(* comment hide *}